Metsera, Inc.

Big pharma’s appetite for the next big play in the mega-blockbuster obesity market seems insatiable, but two companies aim to feed their pipelines with sizeable collaborations announced on 3 March. Ab

Biopharma financing during the fourth quarter of 2024 totaled $16.8bn from 251 deals. Of those, 60 reached $100m or more. The follow-on public offering (FOPO) and venture financing categories tied for

Sionna Therapeutics has multiple drug candidates in the clinic and an ambition to improve cystic fibrosis treatment beyond what Vertex Therapeutics has achieved with its blockbuster portfolio of cysti

If biopharma companies keep up the pace of three initial public offerings in the US per month seen in January, the number of IPOs in 2025 will exceed the 25 first-time offerings that drug developers a